Y. Shimotori et al. / Carbohydrate Research 359 (2012) 11–17
13
6.86 (d, J = 8.6 Hz, 2H, Ph), 7.41 (d, J = 8.6 Hz, 2H, Ph), 7.68 (d,
J = 16.0 Hz, 1H, –C(@O)CH@CH–); 13C NMR (126 MHz, CDCl3):
d = 20.6 (CH3 in OAc at C-2 and C-4), 20.7 (CH3 in OAc at C-3 and
C-6), 61.5 (C-6), 67.8 (C-4), 70.3 (C-2), 72.7 (C-5), 72.8 (C-3), 91.8
(C-1), 113.3 (–C(@O)CH@CH–), 116.0 (Ph), 126.5 (Ph), 130.4 (Ph),
147.3 (–C(@O)CH@CH–), 158.6(Ph), 165.1(–C(@O)CH@CH–),
169.5 (–C@O in OAc at C-2), 169.6 (–C@O in OAc at C-3), 170.2
(–C@O in OAc at C-4), 170.8 (–C@O in OAc at C-6).
NMR (500 MHz, CDCl3): d = 1.92 (s, 3H, CH3 in OAc at C-2), 2.00 (s,
3H, CH3 in OAc at C-3), 2.98 (br, 1H, OH at C-6), 3.53 (m, 1H, H-5),
3.66 (m, 2H, H-4, H-6a), 3.83 (d, J = 10.7 Hz, 1H, H-6b), 3.86 (br,
1H, OH at C-4), 4.98 (t, J = 9.2 Hz, 1H, H-2), 5.13 (t, J = 9.2 Hz, 1H,
H-3), 5.80 (d, J = 9.2 Hz, 1H, H-1), 6.22 (d, J = 16.5 Hz, 1H, –
C(@O)CH@CH–), 6.74 (m, 3H, Ph), 7.39 (d, J = 8.9 Hz, 2H, Ph), 7.60
(d, J = 16.0 Hz, 1H, –C(@O)CH@CH–); 13C NMR (126 MHz, CDCl3):
d = 20.8 (CH3 in OAc at C-2), 21.0 (CH3 in OAc at C-3), 61.8 (C-6),
68.9 (C-4), 70.7 (C-2), 75.7 (C-3), 76.7 (C-5), 92.3 (C-1), 116.4 (–
C(@O)CH@CH–), 128.6 (Ph), 129.1(Ph), 131.1 (Ph), 134.0 (Ph),
147.7 (–C(@O)CH@CH–), 165.2 (–C(@O)CH@CH–), 170.0 (-C@O in
OAc at C-2), 171.5 (-C@O in OAc at C-3). ESI-MS: m/z [M+NH4]+
calcd for C19H26NO9: 412.1602: found: 412.1608.
2.2.3. 2,3,4,6-Tetra-O-acetyl-b-D-glucopyranosyl ferulate (1c)
This compound was synthesized according to procedure de-
scribed for 1a. Instead of trans-cinnamic acid, ferulic acid (388 mg,
2.0 mmol) was glycosylated with TAGB (411 mg, 1.0 mmol) to give
1c (388 mg, 74%) as a white solid. Rf = 0.34 (hexane–EtOAc, 1:1);
½
a 2D0
ꢂ
ꢃ52.7 (c 1.0, THF); IR (KBr): 3382, 2969, 1754, 1638, 1588,
2.3.2. 2,3-Di-O-acetyl-b-
This compound was synthesized according to procedure de-
scribed for 2a. 2,3,4,6-tetra-O-acetyl-b- -glucopyranosyl p-couma-
D-glucopyranosyl p-coumarate (2b)
1515, 1372, 1233, 1098 cmꢃ1 1H NMR (500 MHz, CDCl3): d = 2.05
;
(m, 12H, CH3 ꢁ 4 in OAc at C-2, C-3, C-4, C-6), 3.90 (ddd, J = 9.2,
4.6, 2.3 Hz, 1H, H-5), 3.94 (s, 3H, CH3 in OMe at Ph), 4.13 (dd,
J = 12.6, 2.3 Hz, 1H, H-6a), 4.32 (dd, J = 12.6, 4.6 Hz, 1H, H-6b),
5.18 (t, J = 9.2 Hz, 1H, H-4), 5.22 (t, J = 9.2 Hz, 1H, H-2), 5.28 (t,
J = 9.2 Hz, 1H, H-3), 5.86 (d, J = 9.2 Hz, 1H, H-1), 5.91 (s, 1H, OH),
6.26 (d, J = 16.0 Hz, 1H, –C(@O)CH@CH–), 6.93 (d, J = 8.6 Hz, 1H,
Ph), 7.04 (d, J = 1.7 Hz, 1H, Ph), 7.09 (dd, J = 8.3, 2.0 Hz, 1H, Ph),
7.69 (d, J = 16.0 Hz, 1H, –C(@O)CH@CH–); 13C NMR (126 MHz,
CDCl3): d = 20.6 (CH3 in OAc), 56.0 (OCH3 at Ph), 61.5 (C-6), 67.9
(C-4), 70.3 (C-2), 72.7 (C-3, C-5), 91.9 (C-1), 109.6 (Ph), 113.4 (–
C(@O)CH@CH–), 114.8 (Ph), 123.9 (Ph), 126.5 (Ph), 146.8 (Ph),
147.6 (–C(@O)CH@CH–), 148.6 (Ph), 164.9 (–C(@O)CH@CH–),
169.4 (2-C@O in OAc at C-3 and C-4), 170.0 (–C@O in OAc at C-6),
170.6 (–C@O in OAc at C-2). ESI-MS: m/z [M+NH4]+ calcd for
D
rate (1b) (468 mg, 1.0 mmol) was hydrolyzed with Novozym 435 to
give 2b (267 mg, 65%) as a white solid. Rf = 0.42 (CHCl3–MeOH,
9:1); ½a 2D0
ꢂ
ꢃ49.7 (c 1.0, THF); IR (KBr): 3351, 2921, 1721, 1604,
1246, 1067, 1036 cmꢃ1
;
1H NMR (500 MHz, CD3OD): d = 1.92 (s,
3H, CH3 in OAc at C-2), 2.00 (s, 3H, CH3 in OAc at C-3), 3.53 (m,
1H, H-5), 3.66 (m, 2H, H-4, H-6a), 3.83 (d, J = 10.7 Hz, 1H, H-6b),
4.75 (t, J = 5.7 Hz, 1H, OH at C-6), 4.98 (t, J = 9.2 Hz, 1H, H-2), 5.13
(t, J = 9.2 Hz, 1H, H-3), 5.56 (d, J = 5.7 Hz, 1H, OH at C-4), 5.80 (d,
J = 9.2 Hz, 1H, H-1), 6.22 (d, J = 16.5 Hz, 1H, –C(@O)CH@CH–), 6.74
(d, J = 7.6 Hz, 2H, Ph), 7.39 (d, J = 8.9 Hz, 2H, Ph), 7.60 (d,
J = 16.0 Hz, 1H, –C(@O)CH@CH–); 13C NMR (126 MHz, CD3OD):
d = 20.6 (CH3 in OAc at C-2), 20.8 (CH3 in OAc at C-3), 61.8 (C-6),
68.9 (C-4), 72.4 (C-2), 76.7 (C-3), 78.5 (C-5), 93.3 (C-1), 113.6 (–
C(@O)CH@CH–), 116.9 (Ph), 126.8 (Ph), 131.5 (Ph), 148.5 (–
C(@O)CH@CH–), 161.6 (Ph), 166.8 (–C(@O)CH@CH–), 171.3(–C@O
in OAc at C-2), 172.1 (–C@O in OAc at C-3). APCI-MS: m/z
[M+Na]+ calcd for C19H22NaO10: 433.1116; found: 433.1111.
C24H32NO13: 542.1873; found: 542.1868.
2.2.4. 2,3,4,6-Tetra-O-acetyl-b- -glucopyranosyl sinapinate (1d)
D
This compound was synthesized according to procedure de-
scribed for 1a. Instead of trans-cinnamic acid, sinapinic acid
(448 mg, 2.0 mmol) was glycosylated with TAGB (411 mg, 1.0 mmol)
to give 1d (405 mg, 73%) as a orange solid. Rf = 0.24 (hexane–EtOAc,
2.3.3. 2,3-Di-O-acetyl-b-
This compound was synthesized according to procedure de-
scribed for 2a. 2,3,4,6-di-O-acetyl-b- -glucopyranosyl ferulate (1c)
D-glucopyranosyl ferulate (2c)
1:1); ½a 2D0
ꢂ
ꢃ6.8 (c 1.0, THF); IR (KBr): 3471, 2943, 1751, 1545, 1223,
D
1070 cmꢃ1; 1H NMR (500 MHz, CDCl3): d = 2.07 (m, 12H, CH3 ꢁ 4 in
OAc), 3.91 (ddd, J = 9.2, 4.6, 2.3 Hz, 1H, H-5), 3.93 (s, 6H, OCH3 at
Ph), 4.14 (dd, J = 12.6, 2.3 Hz, 1H, H-6a), 4.32 (dd, J =12.6, 4.6 Hz,
1H, H-6b), 5.18 (t, J = 9.2 Hz, 1H, H-4), 5.22 (t, J = 9.2 Hz, 1H, H-2),
5.28 (t, J = 9.2 Hz, 1H, H-3), 5.82 (s, 1H, OH), 5.87 (d, J = 9.2 Hz, 1H,
H-1), 6.28 (d, J = 16.0 Hz, 1H, –C(@O)CH@CH–), 6.79 (s, 2H, Ph),
7.67 (d, J = 16.0 Hz, 1H, –C(@O)CH@CH–); 13C NMR (126 MHz,
CDCl3): d = 20.5 (CH3 ꢁ 2 in OAc), 20.6 (CH3 in OAc), 56.3 (CH3 in
OCH3 at Ph), 61.5 (C-6), 67.8 (C-4), 70.2 (C-2), 72.6 (C-5), 72.7 (C-3),
91.7 (C-1), 105.4 (Ph), 113.7 (–C(@O)CH@CH–), 125.3 (Ph), 137.8
(Ph), 147.2 (Ph), 147.7 (–C(@O)CH@CH–), 164.8 (–C(@O)CH@CH–),
169.4 (2-C@O in OAc at C-3 and C-4), 170.0 (–C@O in OAc at C-6),
170.6 (–C@O in OAc at C-2). ESI-MS: m/z [M+NH4]+ calcd for
(361 mg, 1.0 mmol) was hydrolyzed with Novozym 435 to give 2c
(361 mg, 82%) as a white solid. Rf = 0.32 (CHCl3–MeOH, 9:1); ½a D20
ꢂ
ꢃ44.8 (c 1.0, THF); IR (KBr) 3464, 3370, 1740, 1248, 1078 cmꢃ1
;
1H NMR (500 MHz, DMSO-d6): d = 1.95 (s, 3H, CH3 in OAc at C-2),
2.01 (s, 3H, CH3 in OAc at C-3), 3.34 (m, 1H, H-5), 3.55 (m, 3H, H-
4, H-5, H-6a), 3.68 (dd, J = 11.2, 3.7 Hz, 1H, H-6b), 3.82 (s, 3H, CH3
in OMe at Ph), 4.66 (s, 1H, OH at C-6), 4.86 (t, J = 9.2 Hz, 1H, H-2),
5.12 (t, J = 9.2 Hz, 1H, H-3), 5.57 (s, 1H, OH at C-4), 5.90 (d,
J = 9.2 Hz, 1H, H-1), 6.46 (d, J = 16.0 Hz, 1H, –C(@O)CH@CH–), 6.80
(d, J = 8.0 Hz, 1H, Ph), 7.14 (dd, J = 8.3, 2.0 Hz, 1H, Ph), 7.35 (s, 1H,
Ph), 7.60 (d, J = 16.0 Hz, 1H, –C(@O)CH@CH–), 9.74 (br, 1H, PhOH);
13C NMR (126 MHz, DMSO-d6): d = 20.4 (CH3 in OAc at C-2), 20.7
(CH3 in OAc at C-3), 55.7 (CH3 in OCH3 at Ph), 60.0 (C-6), 67.9 (C-
5), 70.9 (C-2), 74.9 (C-3), 77.3 (C-4), 91.3 (C-1), 111.3 (Ph), 112.8
(–C(@O)CH@CH–), 115.5 (Ph), 123.9 (Ph), 125.2 (Ph), 147.3 (–
C(@O)CH@CH–), 147.9 (Ph), 150.0 (Ph), 164.8 (–C(@O)CH@CH–),
169.3 (–C@O in OAc at C-2), 169.7 (–C@O in OAc at C-3). ESI-MS:
m/z [M+NH4]+ calcd for C20H28NO11: 458.1662; found: 458.1668.
C25H34NO14: 572.1981; found: 572.1979.
2.3. Regioselective deacetylation with Novozym 435
2.3.1. 2,3-Di-O-acetyl-b-
D
-glucopyranosyl cinnamate (2a)
-glucopyranosyl cinna-
A solution of 2,3,4,6-tetra-O-acetyl-b-
D
mate (1a) (478 mg, 1.0 mmol), MeOH (256 mg, 8.0 mmol) and Nov-
ozym 435 (0.8 g) in tert-butyl methyl ether (10 mL) was stirred for
24 h at 50 °C. The progress of the reaction was monitored with thin
layer chromatography. Upon completion of the reaction, Novozym
435 was filtered off the reaction mixture, and the solvent was then
removed under vacuum. The residue was purified with flash chro-
matography (CHCl3–MeOH, 20:1) to give 2a (386 mg, 98%) as a
2.3.4. 2,3-Di-O-acetyl-b-
This compound was synthesized according to procedure de-
scribed for 2a. 2,3,4,6-di-O-acetyl-b- -glucopyranosyl sinapate
D-glucopyranosyl sinapinate (2d)
D
(1d) (528 mg, 1.0 mmol) was hydrolyzed with Novozym 435 to give
3d (423 mg, 90%) as a white solid. Rf = 0.43 (CHCl3–MeOH, 9:1);
½
a 2D0
ꢂ
ꢃ39.6 (c 1.0, THF); IR (KBr): 3446, 2997, 1740, 1412, 1135,
942 cmꢃ1 1H NMR (500 MHz, DMSO-d6): d = 1.95 (s, 3H, CH3 in
;
white solid. Rf = 0.42 (CHCl3–MeOH, 9:1); ½a D20
ꢂ
ꢃ49.4 (c 1.0, THF);
OAc at C-2), 2.00 (s, 3H, CH3 in OAc at C-3), 3.54 (m, 3H, H-4, H-5,
H-6a) 3.68(m, 1H, H-6b), 3.80 (s, 6H, CH3 ꢁ 2 in OMe at Ph), 4.75
IR (KBr): 3446, 2935, 1751, 1635, 1244, 1074, 1034 cmꢃ1
;
1H